Clinical Trials Browser

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

17 enrolled

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Phase 1 Completed

5 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT00048334 2019-12-12

Depsipeptide to Treat Thyroid and Other Advanced Cancers

Phase 1 Completed

28 enrolled

Tumor-Agnostic

Neoplasms

NCT00094978 2019-12-12

Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum

Phase 1 Terminated

23 enrolled

GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Mesothelioma, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00379639 2019-10-30

A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

Phase 1 Completed

36 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00037817 2019-09-30

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

Phase 1 Completed

34 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT01897012 2019-01-28

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

Phase 1 Completed

26 enrolled

Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01590732 2018-09-19

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

Phase 1 Completed

22 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Clinical Trials

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Depsipeptide to Treat Thyroid and Other Advanced Cancers

Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum

A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma